posdinemab
Jump to navigation
Jump to search
Indications
- treatment of early Alzheimer disease*
* granted Fast Track designation by the FDA on Jan 8, 2025[1]
Dosage
- 15 mg/kg, 30 mg/kg or 60 mg/kg by intravenous infusion
- administered on days 1, 29 & 57[2]
Mechanism of action
- humanized IgG1/kappa phosphorylated tau-directed monoclonal antibody
- binds to CSF ptau-217[1]
More general terms
Additional terms
References
- ↑ Jump up to: 1.0 1.1 1.2 Mendoza B Posdinemab Granted Fast Track Designation by the FDA for Early Alzheimer Disease. Psych Congress Network. Jan 10, 2025 https://www.hmpgloballearningnetwork.com/site/pcn/posdinemab-granted-fast-track-designation-fda-early-alzheimer-disease
- ↑ Jump up to: 2.0 2.1 Galpern WR, Triana-Baltzer G, Li L et al Phase 1 Studies of the Anti-Tau Monoclonal Antibody JNJ-63733657 in Healthy Participants and Participants with Alzheimer's Disease. J Prev Alzheimers Dis. 2024;11(6):1592-1603. PMID: https://www.ncbi.nlm.nih.gov/pubmed/39559872 PMCID: PMC11573813 Free PMC article. Clinical Trial.